Protagonist Therapeutics (NASDAQ:PTGX) Stock Rating Upgraded by Wall Street Zen

Posted by Francis Steltz on Nov 9th, 2026

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued on Saturday, Wall Street Zen reports.

Several other research firms also recently commented on PTGX. Leerink Partners began coverage on Protagonist Therapeutics in a report on Monday, October 12th. They issued an “outperform” rating and a $190.00 price objective for the company. Zacks Research raised shares of Protagonist Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 14th. The Goldman Sachs Group upgraded shares of Protagonist Therapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $110.00 to $186.00 in a report on Monday, August 10th. Weiss Ratings lowered shares of Protagonist Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, October 23rd. Finally, HC Wainwright upped their price target on shares of Protagonist Therapeutics from $170.00 to $221.00 and gave the stock a “buy” rating in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating and sixteen have issued a Buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $166.67.

Get Our Latest Analysis on Protagonist Therapeutics

Protagonist Therapeutics Stock Performance

PTGX opened at $132.04 on Friday. The business’s 50-day simple moving average is $141.52 and its 200 day simple moving average is $117.83. Protagonist Therapeutics has a 52-week low of $76.70 and a 52-week high of $160.81. The firm has a market capitalization of $8.54 billion, a PE ratio of 27.97 and a beta of 1.21.

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported $3.07 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.57. The firm had revenue of $274.41 million during the quarter, compared to the consensus estimate of $238.49 million. Protagonist Therapeutics had a return on equity of 48.62% and a net margin of 62.04%. On average, research analysts forecast that Protagonist Therapeutics will post 4.59 earnings per share for the current year.

Insider Activity at Protagonist Therapeutics

In other news, CEO Dinsesh Patel sold 7,278 shares of the business’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $144.10, for a total transaction of $1,048,759.80. Following the completion of the sale, the chief executive officer owned 522,968 shares in the company, valued at $75,359,688.80. The trade was a 1.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Asif Ali sold 58,629 shares of the business’s stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $141.78, for a total value of $8,312,419.62. Following the sale, the chief financial officer owned 59,003 shares of the company’s stock, valued at approximately $8,365,445.34. This represents a 49.84% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 217,868 shares of company stock valued at $31,638,164 over the last 90 days. Company insiders own 5.19% of the company’s stock.

Institutional Trading of Protagonist Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. TFB Advisors LLC boosted its stake in shares of Protagonist Therapeutics by 3.0% in the third quarter. TFB Advisors LLC now owns 5,394 shares of the company’s stock valued at $760,000 after buying an additional 159 shares during the period. Sumitomo Mitsui Trust Group Inc. grew its position in Protagonist Therapeutics by 7.8% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,760 shares of the company’s stock worth $291,000 after buying an additional 200 shares in the last quarter. GAMMA Investing LLC increased its stake in Protagonist Therapeutics by 7.2% during the 2nd quarter. GAMMA Investing LLC now owns 3,109 shares of the company’s stock worth $381,000 after acquiring an additional 208 shares during the period. Choreo LLC increased its stake in Protagonist Therapeutics by 9.3% during the 3rd quarter. Choreo LLC now owns 2,533 shares of the company’s stock worth $357,000 after acquiring an additional 216 shares during the period. Finally, Keating Financial Advisory Services Inc. bought a new position in Protagonist Therapeutics during the 2nd quarter worth $30,000. 98.63% of the stock is currently owned by institutional investors.

About Protagonist Therapeutics

(Get Free Report)

Protagonist Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops peptide-based medicines, primarily for inflammatory and blood disorders. Its research approach uses engineered peptides designed to act on specific biological targets.

The company’s programs include rusfertide, a hepcidin mimetic being developed for polycythemia vera, and icotrokinra, an oral interleukin-23 receptor antagonist being developed for immune-mediated diseases. Protagonist has entered into licensing and development collaborations for these programs with Takeda and Johnson & Johnson, respectively; they are investigational medicines, not approved treatments.

Founded in 2006 and based in Newark, California, Protagonist is led by co-founder and Chief Executive Officer Dinesh V.